writes Monday’s edition of the Times. Among plus arguments noticeable reliable main shareholder with good track and that the company has great potential for growth through acquisitions, where the next big purchase can be made in the United States. Moreover, one of the business strengths that it is non-cyclical in nature, says the newspaper.
On the minus account harbors a fairly high score, margin pressure in the sector and that there is already high expectations for further acquisitions.
The bottom line is, however, Recipharm growth journey only in its infancy when acquisition opportunities as well as consolidation in the pharmaceutical manufacturing industry is large, according to Dagens Industri.
No comments:
Post a Comment